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Insights into immune responses 
in oral cancer through proteomic 
analysis of saliva and salivary 
extracellular vesicles
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The development and progression of oral cavity squamous cell carcinoma (OSCC) involves complex 
cellular mechanisms that contribute to the low five-year survival rate of approximately 20% among 
diagnosed patients. However, the biological processes essential to tumor progression are not 
completely understood. Therefore, detecting alterations in the salivary proteome may assist in 
elucidating the cellular mechanisms modulated in OSCC and improve the clinical prognosis of the 
disease. The proteome of whole saliva and salivary extracellular vesicles (EVs) from patients with 
OSCC and healthy individuals were analyzed by LC-MS/MS and label-free protein quantification. 
Proteome data analysis was performed using statistical, machine learning and feature selection 
methods with additional functional annotation. Biological processes related to immune responses, 
peptidase inhibitor activity, iron coordination and protease binding were overrepresented in the 
group of differentially expressed proteins. Proteins related to the inflammatory system, transport 
of metals and cellular growth and proliferation were identified in the proteome of salivary EVs. 
The proteomics data were robust and could classify OSCC with 90% accuracy. The saliva proteome 
analysis revealed that immune processes are related to the presence of OSCC and indicate that 
proteomics data can contribute to determining OSCC prognosis.
Oral cancer represents 1 to 2% of all types of cancer worldwide, and oral squamous cell carcinoma 
(OSCC) is the most frequent histopathological type reported among patients1. This disease can affect 
different sites in the oral cavity, such as the tongue, floor of the mouth and cheeks, and smoking and 
alcohol ingestion is responsible for approximately 90% of OSCC cases2–4. Half of the patients with oral 
cancer are diagnosed only when the disease has reached an advanced clinical stage (III/IV), leading to a 
five-year survival rate of only 20% in these cases1,5,6. OSCC prognosis is currently based on the clinical 
staging system of tumor-lymph node-metastasis of the disease (TNM system). However, this system is 
not optimal because tumors may present distinct biological characteristics even at similar developmental 
stages7. Thus, the identification of additional parameters or biological markers that assist with determin-
ing the prognosis of patients with OSCC is essential.
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One promising strategy for the discovery of new biomarkers consists of the identification of the pro-
tein profile of body fluids, such as saliva, which may be used to characterize a specific disease. The rep-
ertoire of disease-related proteins and other molecules can be identified by mass spectrometry. Although 
the use of saliva is not novel, this approach is receiving great interest as a diagnostic fluid because 
harvesting saliva is performed using non-invasive methods. Previous studies reporting the proteomic 
analysis of saliva from healthy individuals have already indicated the potential of this approach for mon-
itoring health8. Furthermore, recent studies have shown that saliva contains many signaling molecules 
that may be indicative of cancer9,10.
Moreover, cancer cells can generate several types of extracellular vesicles, ranging from 30 nm to a few 
micrometers in diameter, which may be shed from the cytoplasmic membrane11. These extracellular ves-
icles (EVs) can deliver molecules (such as proteins, mRNA, microRNA, rRNA, tRNA, DNA and lipids) 
that have been suggested to participate in important intracellular signaling mechanisms even in distant 
target cells11–13. Although many potential biomarkers for oral cancer have been identified in human 
saliva, the role of such molecules in oral cancer is not completely understood10,14–16. Several proteins, 
including CD44, IL-6, IL-8 and defensin-1, have been suggested to be OSCC biomarkers. The expression 
of these molecules has also been reported in other types of cancer, indicating that common cancer cell 
responses may underlie tumor progression17–20. Furthermore, global similarities between the differing 
types of cancer indicate that cancer complexity may reside in the cellular host responses, which could 
indeed influence the mechanisms by which cancer progresses in different individuals.
In the present study, we examined the proteome profile of whole saliva and salivary EVs from patients 
with oral cancer (patients with and without tumor lesions) and healthy individuals by mass spectrom-
etry analysis. Due to significant differences in processes related to inflammatory and humoral immune 
responses, peptidase inhibitor activity, iron coordination and protease binding, the two classes of individ-
uals (healthy vs. OSCC) were distinguished with 90% accuracy based on the proteomics data. Moreover, 
proteome functional annotation revealed that differentially expressed salivary proteins may indeed be 
related to cell-to-cell signaling and cellular interaction mechanisms.
Results
Differentially expressed proteins in whole saliva from oral cancer patients showed potential 
roles in peptidase regulation and immune responses. We analyzed the whole salivary proteome 
and the proteome from salivary EVs isolated from healthy individuals and oral cancer patients (“lesion” 
plus “no lesion” individuals). The clinical classifications of the patients are listed in Supplemental Table 
1. Relative protein quantification was performed using the label-free quantification (LFQ) method, and 
our data showed high reproducibility (Supplemental Figure 1 and Supplemental Figure 2). This analysis 
resulted in the identification of 507 proteins after data pre-processing (excluding contaminants, reverse 
sequences and only identified by site) (Supplemental Table 2) from which 147 proteins had at least five 
valid LFQ intensity values in at least one group (healthy, n = 9, or oral cancer, n = 21). The filtered dataset 
containing 147 proteins was subjected to further data analysis using a one-way ANOVA test (p < 0.05) 
resulting in 44 proteins showing differential expression. In addition, ANOVA p-values corrected by 
Storey´s method are shown (Fig.  1, Supplemental Table 3). Most of these differentially expressed pro-
teins showed reduced expression in oral cancer patients. Additionally, nineteen proteins were exclusively 
identified in the healthy group, and 247 proteins were exclusively identified in the oral cancer group.
The results of GO enrichment analysis of the differentially expressed proteins (44 proteins, ANOVA 
p < 0.05) showed a significant overrepresentation of biological processes related to acute inflammatory 
response (p-value = 3.3E-07), regulation of humoral response (p-value = 3.1E-06) and regulation of 
hydrogen peroxide metabolic processes (p-value = 1.67E-04). Cellular components related to cytoplasmic 
membrane-bounded vesicle lumen (p-value = 5.9E-10) and endocytic vesicle lumen (p-value = 6.5E-06) 
components were overrepresented in the dataset. According to the IPA (Ingenuity® Systems, http://www.
ingenuity.com) analysis, the molecular function cell-to-cell signaling and interaction was overrepresented 
in the dataset of differentially expressed proteins (Supplemental Table 4). Furthermore, overrepresented 
molecular function GO terms included humoral immune responses, peptidase inhibitor activity and 
protease binding (p-value < 0.05). A network of the overrepresented GO terms is shown in Fig. 2.
Proteomic data analysis of whole saliva from healthy and oral cancer patients permitted 
classification of patients. Principal component analysis (PCA) was performed using the proteome 
LFQ data (no missing values) from whole saliva and indicated that groups of healthy individuals can 
be distinguished from the oral cancer individuals (Supplemental Figure 3). Therefore, we applied the 
support vector machines (SVM) method to the proteome dataset to evaluate whether the dataset could 
classify the two groups of individuals. Furthermore, proteins that could classify the two groups of indi-
viduals (healthy and OSCC) were identified through the application of the feature selection method. For 
the generation of the classification model using SVM, 571 attributes (protein intensity normalized by 
z-score) and 30 instances (individuals) were used, and a 3-fold cross-validation method was performed. 
Our classification model resulted in high precision (0.925), recall (0.9), and ROC (0.929) and a Kappa 
value of 0.78. The proteins identified as the best features for data classification are listed in Table 1 with 
their functional annotations.
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Oral cancer patients with lesions and without tumor lesions have differing proteome reper-
toires. The influence of the presence or absence of tumor lesions in patients diagnosed with oral can-
cer was investigated. Among the total 507 proteins identified, 13 proteins were identified as differentially 
expressed between the “lesion” (n = 12) and “no lesion” (n = 9) groups (Fig. 3). A group of 38 proteins 
were identified exclusively in the saliva of patients with lesions, and 5 proteins were exclusively identi-
fied in the group of patients without lesions, considering proteins identified in at least two individuals. 
According to IPA knowledge base information, some of the differentially expressed proteins may play 
roles in processes related to cell movement, morphology and cell death (Supplemental Table 5).
Proteomic profiling of salivary extracellular vesicles indicated overrepresentation of antigen 
binding and enzyme inhibitory functions. The size distribution of salivary EV samples was meas-
ured using the NTA, revealing the presence of EVs with an average size of 177.19 nm (SD = 17.22 nm) 
(Fig. 4A). Western blotting analysis for flotilin-1 indicated a greater abundance of this marker protein in 
the isolates of EVs (Fig. 4B). Furthermore, the structure of isolated EVs was observed by transmission 
electron microscopy (TEM-HR), which revealed that the EVs were intact after isolation (Fig.  4C). A 
total of 381 proteins were identified by mass spectrometry in the EV proteome from the two groups of 
individuals (healthy (n = 10) and oral cancer (n = 7)) (Supplemental Table 6). Considering proteins that 
showed a minimum of three valid expression values in at least one group, 139 proteins were subjected to 
statistical analysis. Eight proteins from the EVs were differentially expressed (ANOVA, p < 0.05) between 
the two groups (Fig. 5). Among the total 381 proteins identified, 18 proteins were exclusively detected in 
the healthy group and 4 proteins were exclusively identified in the oral cancer group, considering pro-
teins identified in at least two individuals. GO enrichment analysis revealed that the biological processes 
“antigen binding,” “enzyme inhibitor” and “endopeptidase regulatory functions” were overrepresented in 
the EVs proteome (Supplemental Figure 4, Supplemental Table 7).
Figure 1. Differentially expressed proteins in whole saliva from human oral cancer. LFQ intensity 
values of the salivary proteins identified from oral cancer patients were compared to the LFQ values of 
salivary proteins identified from healthy individuals, and proteins with a significant differential abundance 
were detected using the ANOVA (p < 0.05) method. Clustering analysis of the data was performed using a 
Euclidian distance method for the z-score normalized LFQ values. The z-score normalized values are shown 
in a heat map that represents the variation in protein abundance between the analyzed samples. Groups of 
oral cancer and healthy individuals and the corresponding protein names are indicated.
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Proteomics data revealed prognosis-associated proteins and functional connections among 
protein-coding genes and drugs. The intensity values of the differentially expressed proteins identi-
fied in our study were used to analyze survival time. We observed that among the differentially expressed 
proteins, only the protein peptidyl-prolyl cis-trans isomerase A (PPIA, also known as cyclophilin-A) was 
statistically significant in the analysis of the mean survival time (Fig.  6). Notably, reduced abundance 
of PPIA appears to be a factor that may predict poor prognosis of OSCC patients. Upon observing that 
differentially expressed proteins may indeed possess prognostic value for patients with OSCC, we further 
investigated functional connections associated with these proteins.
Using the cMAP database21, eight compounds were identified as significantly related to alterations in 
the expression of the genes that code for the differentially expressed proteins (Supplemental Table 8). 
Figure 2. Network of overrepresented GO terms in the dataset of differentially expressed proteins in the 
whole saliva proteome. Proteins identified as differentially expressed in the whole saliva of patients with 
oral cancer and healthy individuals were subjected to a GO term enrichment analysis using the ClueGO 
plugin. Overrepresented GO terms (p-value < 0.05) for Biological Processes, Cellular Components and 
Molecular Function categories were visualized using the Cytoscape suite. The most significant GO terms 
within the dataset of significantly enriched terms are indicated in red font.
UniProt_AC
Gene 
names Protein names
Differentially 
expressed*(Yes/No)
P01034 CST3 Cystatin-C No
P23280 CA6 Carbonic anhydrase 6 No
P32926 DSG3 Desmoglein-3 Yes
Q02818 NUCB1 Nucleobindin-1 No
Q8TDL5 BPIFB1 BPI fold-containing family B member 1 Yes
Q9HC84 MUC5B Mucin-5B Yes
Q9NQ38-3 SPINK5 Serine protease inhibitor Kazal-type 5 Yes
P20591 MX1 Interferon-induced GTP-binding protein Mx1 No
Table 1.  Proteins of whole saliva with potential for classification of oral cancer individuals were 
selected based on feature and attribute selection methods. *Proteins significantly differentially expressed in 
the whole salivary proteome or in EVs salivary proteome analysis.
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The small compounds terazosin, 15-delta prostaglandin J2, PNU-020031, acyclovir, dextromethorphan, 
yohimbic acid, benzthiazide and pseudopelletierine were ranked as the most significant compounds, 
with p-values < 0.01.
Furthermore, a cross-cancer analysis of the frequency of genetic alterations (mutation, deletion, 
amplification and multiple alterations) in the genes that code for the differentially expressed proteins in 
the saliva of OSCC patients indicated that in general, mutations in the genes coding for the differentially 
expressed proteins occur in less than 30% of the cases of head and neck cancer in datasets reported 
through the cBioPortal for cancer genomics (Supplemental Figure 5a). The frequency of alterations in 
the genes coding for proteins reported as classificatory for OSCC through the feature selection method 
is less than 15% (Supplemental Figure 5b) according to the information available from cBioPortal.
Furthermore, S-score (www.bioinformatics-brazil.org/S-score/) classification analysis of the list of 
differentially expressed proteins and proteins that were robust for classification of OSCC indicated that 
depending on the types of cancer compared, the same proteins may play roles as tumor oncogenes or 
tumor suppressors. The S-score calculation revealed that the genes coding for the differentially expressed 
proteins in the salivary proteome of OSCC patients display expression patterns that are most similar to 
the gene expression profile of the ovarian cancer dataset (Supplemental Figure 6).
Discussion
The shotgun proteome analysis of saliva from healthy and oral cancer individuals revealed the identity 
of hundreds of proteins that support previous studies of the intricate effects of immune-response mech-
anisms in tumor development. Statistical analysis of the proteomics data revealed the modulation of 
expression levels of proteins related to networks and pathways that control immune responses in patients 
with oral cancer (Fig. 2).
Jessie and colleagues have explored the aberrant expression of proteins in the saliva of OSCC patients15, 
and the proteins serotransferrin, hemopexin, alpha-1beta-glycoprotein, alpha-1-antitrypsin, haptoglobin, 
Figure 3. Differentially expressed proteins in response to the presence or absence of tumors in patients 
diagnosed with oral cancer. LFQ intensity values (log2) of the salivary proteins identified from diagnosed 
oral cancer patients with tumors (with lesion) were compared to patients without tumors (no lesion). 
Differentially expressed proteins were detected using the ANOVA method (p < 0.05). A Euclidean distance 
clustering analysis of these data was performed, and the differential protein abundance is shown in the heat 
map of normalized z-score values.
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fibrinogen β , complement C3 and transthyretin were detected in the saliva of OSCC patients15, in agree-
ment with our proteomics results presented here. Of note, Jessie performed a very similar protein extrac-
tion procedure to that used in our present study, which is important for the establishment of a panel 
of biomarkers in biofluids. Haptoglobin and alpha-1-antitrypsin have previously been associated with 
OSCC in tissue samples and are known components of the acute-phase response, generally produced 
in the liver in response to the effects of cytokines15,22. However, studies of blood serum samples have 
indicated that acute-phase proteins, including complement C3 and haptoglobin, correlate with the pro-
gression of breast cancer, small cell lung carcinoma and lung adenocarcinoma23.
Previous proteomic analysis of human saliva from healthy individuals has revealed that biological 
processes associated with metabolic and regulatory pathways are overrepresented24, with nearly 50% of 
the proteins functionally associated with metabolism and energy pathways, protein metabolism and cell 
communication16. Therefore, the biological processes overrepresented in our dataset of salivary proteins 
from OSCC patients may indeed represent specific cellular responses and do not represent common 
features of the healthy saliva proteome.
Figure 4. Extracellular vesicles isolated from saliva. Extracellular vesicles were isolated from the saliva 
of healthy and oral cancer patients using ultracentrifugation. (A) Nanoparticle tracking analysis of the 
extracellular vesicles isolated from healthy individuals (C4, C6, C10) and oral cancer patients (T2, T5, T16); 
(B) Immunochemical detection of the protein flotilin-1, a protein marker of extracellular vesicles, in the 
whole saliva proteome (S) and in the proteome of extracellular vesicles (EV); (C) Transmission electron 
microscopy of isolated extracellular vesicles using a negative staining method.
www.nature.com/scientificreports/
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Figure 5. Proteins from extracellular vesicles with a significant differential abundance between healthy 
and oral cancer groups. Extracellular vesicles were isolated from the saliva of healthy and oral cancer 
individuals, and the EV protein content was analyzed by shotgun proteomics. Proteins with a significant 
differential abundance between healthy and oral cancer groups were identified using the label-free 
quantification (LFQ) method (ANOVA, p < 0.05). The Euclidean distance clustering method was used to 
visualize the variations in the protein abundance between the samples and is shown as normalized z-score 
log2 LFQ values in a heat map.
Figure 6. PPIA survival function from lifespan data. Kaplan-Meier curves demonstrate that patients with 
a PPIA low profile succumbed to the disease much earlier than those with a high profile. After 1.5 years, 
approximately 40% of the low profile patients survived, but all subjects in the high intensity group were alive 
at follow-up. A log-rank test shows significant differences between pairs, with p-value < 0.05. The number of 
individuals included in the analysis is shown in the figure legend.
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Moreover, knowledge available on the cBIOPortal indicated that most protein coding genes for the 
differentially expressed proteins in the OSCC phenotype have a genetic mutation frequency of less 
than 30% in head and neck tumors. Furthermore, the results of the S-score analysis performed for the 
same dataset of protein coding genes (Supplemental Figure 6a) and proteins that may classify OSCC 
(Supplemental Figure 6b) indicated that complete agreement does not exist between the gene expres-
sion patterns of these genes in different types of tumors. No clear indication exists regarding the role 
of these genes in OSCC as putative oncogenes or tumor suppressors. However, the expression pattern 
(up- or down-regulation) of the differentially expressed protein coding genes in OSCC matched the 
gene expression pattern from six putative oncogenes and suppressor genes in an ovarian cancer dataset. 
Notably, tumorigenesis in ovarian carcinoma occurs through an epithelial-to-mesenchymal transition, in 
a manner similar to the tumorigenesis observed in OSCC25.
The high abundance of the proteins complement C3, complement factor B (CFB) and complement 
C4-B in the saliva of OSCC patients (Supplemental Table 2) has also previously been observed in tissue 
samples16. Complement activation has recently been shown to occur in ovarian cancer cells due to an 
autocrine effect that produces complement C3 protein, which leads to alterations in the tumor microen-
vironment by increasing the number of myeloid-derived suppressor cells and reducing the number of 
cytotoxic T cells that infiltrate into the tumor, which promotes tumor growth26. According to our signa-
ling network analysis, complement C3 may be autoactivated and bind to the CFB protein, inducing the 
activation of the complement system (Supplemental Figure 7). Complement C3 has also been suggested 
to contribute to the secretion of prostaglandin E2 (PGE2) in aberrant immune responses during induced 
inflammation in mammals27. Furthermore, the overexpression of macrophage migration inhibitory factor 
(MIF) in the saliva from OSCC patients may also correlate with inflammatory responses through altera-
tions in cell movement, adhesion, proliferation and invasion in head and neck squamous cell carcinoma28 
via its functional role activating CD74 protein29. As a general activator of the immune response, MIF can 
overstimulate the secretion of prostaglandin E2 (PGE2) in endometriotic stromal cells30 and has direct 
and indirect effects on tissue remodeling and angiogenesis31.
Furthermore, the proteome of salivary EVs displays overrepresentation of proteins related to special-
ized vesicular structures secreted by the cells, including “membrane-bound vesicle” (corrected p-value = 
5.44E-11), “extracellular organelle” (corrected p-value = 4.23E-10), “extracellular membrane-bound orga-
nelle” (corrected p-value = 4.23E-10) and “extracellular vesicular exosome” (corrected p-value = 5.43E-10). 
GO biological processes overrepresented in the proteome of EVs included “leukocyte migration involved 
in inflammatory response” (corrected p-value = 0.0011) and “chemokine biosynthetic process” (cor-
rected p-value = 0.0031). Molecular functions related to “lipoprotein particle receptor binding” (corrected 
p-value = 0.0030), “peroxidase activity” (corrected p-value = 0.0032) and “oxidoreductase activity” (cor-
rected p-value = 0.0032) are overrepresented in the proteome of EVs (Supplemental Figure 4, Supplemental 
Table 7). Interestingly, the proteome of EVs isolated from the OSCC patients was enriched in proteins with 
molecular and cellular functions related to “molecular transport,” mainly comprising transport of metals, 
and “cellular growth and proliferation” (Supplemental Table 9). These results indicate that salivary EVs 
may transport signaling molecules in the tumor microenvironment and may attract inflammatory cells to 
the tumor site by chemotactic mechanisms, which may be important in the subsequent immunoediting 
of inflammatory cells32. The study of the function of these molecules secreted by inflammatory cells may 
better explain how cancer cells can benefit from the function of the inflammatory system. Furthermore, 
tumor-derived EVs may be related to the formation of a pre-metastatic niche and signaling events in 
cell-to-cell communication33,34 through feedback loops between inflammation and tumor growth, possibly 
involving proteins such as STAT3 and IL-6R in the processes of cancer invasion and metastasis35.
The salivary proteome analysis from OSCC patients with and without lesions indicated that patients 
with active oral malignant lesions have a higher abundance of proteins related to a highly invasive phe-
notype and an immune response (Fig. 3, Supplemental Table 10). Among these proteins, we identified 
matrix metalloproteinase-9 (MMP-9), protein S100A9, myosin-9 (NMMHC II-a) and Rab GDP disso-
ciation inhibitor beta (Supplemental Figure 8). Overexpression of MMP-9 has been detected in saliva 
of OSCC patients and has been implicated in promoting the invasive behavior of colon cancer cells14,36, 
pathological neovascularization and increased cell proliferation in other types of cancer37.
Furthermore, the protein S100A9, which functions as a heterodimer with S100A8, is related to the 
regulation of immune responses and increases in cell proliferation and motility in multiple cancers38. 
Overexpression of S100A9 has been shown to increase the size and volume of skin tumors39 and has also 
been related to chemo-attraction of leukocytes and macrophages, which may trigger pro-inflammatory 
responses in the tumor microenvironment38. However, more recent evidence has demonstrated that the 
S100A9/S100A8 heterodimer may actually function as a suppressor of acute inflammatory responses and 
contribute to reducing the gene expression of IL6, IL1-beta and TNF alpha40.
Our results indicate that PPIA protein is less abundant in the whole saliva of OSCC patients and is 
the top performing prognostic candidate protein; however, further validation in a larger population is 
ongoing. Previous studies have suggested that PPIA plays important roles in several mechanisms, includ-
ing protein folding, trafficking and T-cell activation41.
We also observed modulation of proteins related to the production of vesicles and cytoskeleton 
dynamics. The high abundance of the Rab GDP dissociation inhibitor beta (Rab GDI) protein in the 
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OSCC salivary proteome may indicate an increased need by cancer cells for the generation and secretion 
of EVs; Rab GDI has been suggested to be an important element in the control of vesicle trafficking42.
Furthermore, overexpression of the myosin-9 protein in patients with tumor lesions reinforces the 
suggested role of myosin-9 in cancer progression through affecting cell migration and actin cytoskeleton 
remodeling by interacting with the protein Arl13b43. Additional evidence has indicated that myosin-9 
is involved in the directional migration of immune cells, including neutrophils44, and movement of T 
lymphocytes through the endothelial junctions45. In breast cancer cells, functional inhibition of myosin-9 
results in impaired cell invasion46. In our study, myosin-9 was identified in 14 of the 17 EV samples, 
indicating that myosin-9 may be important in the regulation of the dynamics and organization of the 
cytoskeleton structures of the EVs secreted by normal and cancer cells.
The fact that OSCC individuals without tumor lesions still exhibit a salivary proteomic repertoire that 
differs from the healthy group is an indicator that the host response continues to be at least partially 
modulated once the individuals develop cancer or in response to the medical procedures performed in 
non-lesion patients.
Our results indicate that differentially expressed salivary proteins might be related to humoral immune 
responses, which in turn may be important for oral tumor development and indicate tumor progression. 
The proteome of salivary EVs also displayed the presence of proteins with functions related to an inflam-
matory response in addition to transport of metals and cellular growth and proliferation.
Therefore, the proteomic analysis of whole saliva from healthy individuals and OSCC patients indi-
cated that the composition of saliva may indeed reflect the response of individuals diagnosed with oral 
cancer. The salivary composition of the patients diagnosed with OSCC is different from the saliva of 
healthy individuals, independently of the presence of the tumor itself, given that the saliva of patients 
without lesions also exhibited overexpression of known cancer-related proteins.
However, the mechanisms by which the saliva components and the immune cells interact to modulate 
the cellular responses in the cancer cells is not completely understood. An understanding of the role of 
extracellular vesicles in this cell-to-cell communication may reveal the mechanisms by which immune 
responses and inflammatory cells contribute to positively affect tumor growth.
Methods
Saliva collection and preparation. The study was approved by the ethics review board of the 
Instituto do Câncer do Estado de São Paulo (ICESP), Octavio Frias de Oliveira, ICESP, São Paulo, SP, 
Brazil and Plataforma Brasil, and written informed consent was obtained from all participants. The meth-
ods the present study were performed in accordance with the approved guidelines, and experimental 
protocols were approved by the ethics committee of the ICESP. Saliva samples were obtained voluntarily 
from healthy individuals (n = 10) and oral squamous cell carcinoma (OSCC) patients (n = 24), including 
patients who had undergone surgical resection (designated as “no lesion,” n = 10) and patients who had 
active oral malignant lesions (designated as “lesion,” n = 14) at the time of saliva collection. The clinical 
and pathological information for these oral cancer patients is summarized in Supplemental Table 1. 
Individuals first rinsed their mouths with 5 mL of drinking water and then harvested the saliva into a 
glass recipient. The saliva samples were aliquoted in 2 mL tubes and immediately frozen at − 80 °C. The 
samples remained at − 80 °C for long term storage.
Whole saliva protein extraction. Saliva was initially centrifuged for 5 min at 1,500 × g, 4 °C to 
remove intact cells and debris. A volume of 100 μ L of whole saliva was used in the protein extraction 
procedure, which was performed by homogenizing the whole saliva with 100 μ L of urea buffer (100 mM 
Tris-HCl pH 7.5, 8 M urea, and 2 M thiourea) containing the cOmplete Mini Protease Inhibitor Cocktail 
(Roche, Auckland, New Zealand), 5 mM EDTA, 1 mM PMSF and 1 mM DTT. The samples were soni-
cated for 10 min and centrifuged at 10,000 × g for 5 min. Total protein was quantified using a Bradford 
assay kit (Bio-Rad, São Paulo, Brazil).
Salivary EV isolation and protein extraction. Isolation of EVs was performed based on previously 
described methods47,48. Briefly, 1 mL of saliva was diluted at a proportion of 1:1 in phosphate buffered 
saline (PBS) containing protease inhibitors (1 mM PMSF, 5 mM EDTA, and cOmplete Mini Protease 
Inhibitor Cocktail) and 1 mM DTT and centrifuged at 200 × g for 5 min. The supernatants were cen-
trifuged in consecutive steps of 2,000 × g for 10 min, 3,500 × g for 10 min, and 10,000 × g for 90 min, 
followed by a final ultracentrifugation step at 100,000 × g for 90 min. All centrifugation steps were per-
formed at 4 °C. Isolated EVs were maintained at − 80 °C in PBS for microscopic and nanoparticle track-
ing analysis or were suspended in 30 μ L of urea buffer (50 mM Tris-HCl pH 7.5, 8 M urea, 2 M thiourea, 
and 1 mM DTT) for protein extraction. Samples in urea buffer were sonicated for 5 min at room tem-
perature. Protein quantification was performed using a Bradford assay kit (Bio-Rad, São Paulo, Brazil).
Immunoblotting detection. The presence of the EV marker flotilin-1 was verified by western blot-
ting. Whole saliva and EV protein extracts were separated by 12.5% SDS-PAGE and transferred onto a 
nitrocellulose membrane (GE Healthcare, WI, USA), which was blocked in 1% BSA for 2 h at room tem-
perature followed by incubation with the primary rabbit anti-flotilin-1 antibody (1:5000) (Sigma-Aldrich, 
MO, USA) and the secondary horseradish peroxidase-conjugated anti-rabbit IgG antibody (1:2000) 
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(Sigma-Aldrich, MO, USA). Protein detection was performed by chemiluminescence using an ECL kit 
(Amersham Biosciences, NJ, USA).
Transmission electron microscopy. Salivary EV preparations (1 × 10E8 particles·mL−1) were sus-
pended in PBS and adsorbed onto glow positively charged (15 mA for 25 s) holey carbon coated copper 
grids (Ultrathin carbon film mesh 400 copper grid). Negative staining was performed with freshly pre-
pared 2% aqueous uranyl acetate. EVs were imaged using a JEM-3010 transmission electron microscope 
equipped with a tungsten filament and operated at an acceleration voltage of 300 kV.
Nanoparticle tracking analysis (NTA). NTA measurements of the EVs were performed with a 
NanoSight NS300 (NanoSight, Amesbury, United Kingdom) equipped with a sample chamber with a 
532-nm green laser. The samples were measured at room temperature in PBS for 60 s with camera gain 
adjustments appropriate for the correct focusing of the EVs. The software NTA 2.3 Build 0013 was used 
for data capture and analysis. Nanoparticle sizing and concentrations were determined based on the 
Brownian motion of the individual particles and light scattering measurements.
Mass spectrometry analysis. Whole saliva protein (10 μ g) and salivary EV protein (2 μ g) extracts 
were reduced, alkylated, trypsin digested and desalted according to previous protocols49,50. Tryptic-digested 
peptides were dried in a speed-vac instrument and identified in an ETD enabled LTQ Orbitrap Velos 
mass spectrometer (Thermo Fisher Scientific, Bremen, Germany) connected to the EASY-nLC system 
(Proxeon Biosystem, West Palm Beach, FL, USA) through a Proxeon nanoelectrospray ion source in 
a data dependent mode. Peptides were separated by a 2–30% acetonitrile gradient in 0.1% formic acid 
using an analytical PicoFrit Column (20 cm × ID75 μ m, 5 μ m particle size, New objective) at a flow rate 
of 300 nl/min over 40 min. The nanoelectrospray voltage was set to 2.2 kV, and the source temperature 
was 275 °C. All instrument methods for the LTQ Orbitrap Velos were run in the data-dependent analysis 
(DDA) mode. The full scan MS spectra (m/z 300–1,600) were acquired in the Orbitrap analyzer after 
accumulation to a target value of 1e6. The resolution in the Orbitrap was set to r = 60,000. The 20 most 
intense peptide ions with charge states of ≥ 2 were sequentially isolated to a target value of 5,000 and 
fragmented in the linear ion trap by low-energy CID (normalized collision energy of 35%). The signal 
threshold for triggering an MS/MS event was set to 1,000 counts. Dynamic exclusion was enabled with 
an exclusion size list of 500, exclusion duration of 60 s, and a repeat count of 1. An activation q = 0.25 
and activation time of 10 ms were used.
Proteomics data analysis. Protein identification was performed with the Andromeda search algo-
rithm within the MaxQuant v.1.3.0.3 software against the UniProt Human Protein Database (Release: 
June 2013, 88,820 sequences). The search parameters were set to a maximum of two missing cleavages, 
with a maximum error tolerance of 6 ppm for MS search and 0.5 Da for MS/MS search. Acetylation and 
Oxidation were set as variable modifications, and Carbamidomethylation was set as a fixed modification. 
Label-free protein quantification was performed using a previously described label-free quantification 
(LFQ) algorithm implemented in the MaxQuant software with a 2 min window for matching between 
runs and maximum 1% peptide and 1% protein FDR51,52. Protein intensity values were normalized using 
the LFQ algorithm available through the MaxQuant program and used to further identify differentially 
expressed proteins. Statistical analysis of the data was performed using Perseus v.1.2.7.4 software. Protein 
identification datasets were pre-processed for the exclusion of contaminant entries and reverse sequences 
identification and only identified by site entries. The proteome dataset corresponding to sample T22 was 
excluded from further statistical analysis due to its outlier behavior (modified z-score > 3) considering 
the number of proteins identified by mass spectrometry. LFQ intensity values were log2 transformed; 
the dataset was filtered by minimum valid values (unless otherwise indicated in the text, the minimum 
valid values filter was set to 3) in at least one group, and statistical significance was assessed by applying 
a one-way ANOVA method to identify differentially expressed proteins. Storey´s method53 (FDR < 0.05 
and bootstrap estimation of λ ) was further applied for q-value calculations through multiple hypothesis 
testing correction of calculated ANOVA p-values.
Additionally, data classification and feature selection analysis were performed using the Weka v.3 suite 
(http://www.cs.waikato.ac.nz). The support vector machine (SVM) method was applied using a sequential 
minimal optimization (SMO) algorithm (Polykernel –c250007 –E1.0) for training the SVM, using 66% 
dataset split as the training dataset, which includes the intensity values of the protein hits normalized by 
the z-score. The feature selection method Greedy Stepwise (forwards; -T -1.7976931348623157E308 -N 
-1) with Filtered Subset Evaluator as attribute estimator was applied for the z-score normalized protein 
intensity values for the dataset without any missing data. The dataset corresponding to sample T22 was 
excluded from this analysis due to its outlier behavior.
Functional annotation of the identified proteins was performed using IPA (Ingenuity® Systems, 
http://www.ingenuity.com). Significant interactions and pathways associated with datasets were deter-
mined by Fisher´s exact test. Overrepresented gene ontology (GO) functional categories were identi-
fied through the ClueGO v.2.0.6 plugin, using the hypergeometric test and p-value correction with the 
Benjamini-Hochberg method. Global Homo sapiens GO annotation (GO release 12.07.2013) was used 
as a background annotation database, and the significance threshold was set as 0.05. Overrepresented 
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terms were visualized using the Cytoscape (v.2.8.3) software platform54. The raw files and protein target 
database were deposited in the Peptide Atlas data repository and can be accessed through the link http://
www.peptideatlas.org/PASS/PASS00317.
Assessment of prognostic protein candidates and functional connections associated with the 
identified proteins. Protein LFQ intensity values were used to calculate the odds ratio for the proteins 
identified with differential abundance in the saliva of OSCC patients. The odds ratio, p-values and confi-
dence intervals were calculated, and proteins with an odds ratio p-value of lower than 0.05 were further 
considered in a survival analysis. The LFQ intensity values were used for the analysis of the odds ratio for 
the subset of differentially expressed proteins. The median LFQ intensity values were calculated and used 
as a threshold for dichotomizing the values into two categories associated with low or high intensity mean 
values using the SPSS (Statistical Package for the Social Sciences) 17 software package. Survival curves 
were created using the Kaplan-Meier method55 with comparisons by the log-rank test. Furthermore, our 
analysis of possible connections between the differentially expressed proteins and small bioactive mole-
cules was performed using the connectivity map (cMAP; https://www.broadinstitute.org/cmap/) build 2 
database. Salivary proteins that were up- and downregulated in OSCC patients were used as input data 
for the prediction of common gene expression changes that may occur in response to drugs, genes or pro-
teins. Several drugs were predicted to influence the expression of these candidate protein coding genes.
Additionally, we performed a cross-cancer analysis of the frequency of genetic alterations (mutation, 
deletion, amplification and multiple alterations) in the genes that code for the differentially expressed 
proteins in the saliva of OSCC patients using cBioPortal (www.cbioportal.org). Moreover, protein-coding 
genes that corresponded to differentially expressed proteins identified through our proteomic approach 
and the proteins with potential for data classification were used as input data for the prediction of their 
roles as oncogenes or tumor suppressor genes in different types of cancer using the S-score system (www.
bioinformatics-brazil.org/S-score/)56.
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